

Alistair Scott Hall

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7327412/alistair-scott-hall-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

1,497
citations

11
h-index

19
g-index

19
ext. papers

1,734
ext. citations

14.9
avg, IF

2.97
L-index

#	Paper	IF	Citations
19	Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. <i>Anesthesiology</i> , 2014 , 120, 564-78	4.3	509
18	Common variants at 10 genomic loci influence hemoglobin A _{1c} levels via glycaemic and nonglycaemic pathways. <i>Diabetes</i> , 2010 , 59, 3229-39	0.9	314
17	Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2011 , 90, 9-17	9.9	203
16	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <i>Lancet, The</i> , 2002 , 360, 1037-43	4.0	188
15	Gender bias in acute coronary syndromes. <i>Current Vascular Pharmacology</i> , 2010 , 8, 276-84	3.3	59
14	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. <i>Heart</i> , 2007 , 93, 1081-6	5.1	44
13	The assessment of left ventricular hypertrophy in hypertension. <i>Journal of Hypertension</i> , 2006 , 24, 1223-30	3.0	37
12	The UK DNA banking network: a "fair access" biobank. <i>Cell and Tissue Banking</i> , 2010 , 11, 241-51	2.2	35
11	Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service?. <i>International Journal of Cardiology</i> , 2005 , 100, 229-40	3.2	34
10	Real-time monitoring of coronary care mortality: a comparison and combination of two monitoring tools. <i>International Journal of Cardiology</i> , 2005 , 100, 301-7	3.2	27
9	The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT). <i>European Journal of Heart Failure</i> , 2002 , 4, 495-9	12.3	17
8	Angiotensin receptor blockers should be regarded as first-line drugs for stroke prevention in both primary and secondary prevention settings: no. <i>Stroke</i> , 2009 , 40, 3161-2	6.7	8
7	Modernising medical careers, medical training application service, and the postgraduate medical education and training board: time for the emperors to don their clothes. <i>Lancet, The</i> , 2007 , 369, 967-8	4.0	8
6	Comparison of losartan and captopril in ELITE II. <i>Lancet, The</i> , 2000 , 356, 851; author reply 852-3	4.0	5
5	Medical training in the UK: sleepwalking to disaster. <i>Lancet, The</i> , 2007 , 369, 1673-5	4.0	3
4	RAS blockers: Does sex matter? Re: Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure - A population study: Marie Hudson et al. <i>European Journal of Heart Failure</i> 9 (2007) 602-609. <i>European Journal of Heart Failure</i> , 2007 , 9, 963-4; author reply 964	12.3	2
3	Renin-angiotensin system and cardiovascular risk. <i>Lancet, The</i> , 2007 , 370, 23-4; author reply 24-5	4.0	2

- 2 The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. *Cardiovascular Drugs and Therapy*, **2021**, 1 3.9 2
- 1 Telmisartan in high-risk patients intolerant of ACE inhibitors. *Lancet, The*, **2009**, 373, 458; author reply 459 4.0